Evoke Pharma INC Form 4 insider transactions

Evoke Pharma's Chief Financial Officer, Mark Kowieski, reports the acquisition of 13,000 stock options in the company.

Marilyn R. Carlson, Chief Medical Officer of Evoke Pharma, acquired 11,000 stock options on January 28, 2025, according to a Form 4 filing.

Director Benjamin C. Smeal acquired stock options in Evoke Pharma, Inc. on October 18, 2024.

Mark Kowieski, CFO of Evoke Pharma, acquired stock options on August 7, 2024.

Marilyn R. Carlson, Chief Medical Officer of Evoke Pharma, reports the acquisition of stock options.

Evoke Pharma's CEO, Matthew D'Onofrio, was granted stock options to purchase 64,840 shares of common stock.

Director Malcolm R. Hill reports the acquisition of stock options in Evoke Pharma, Inc.

Director Cam L. Garner acquired 17,750 stock options in Evoke Pharma Inc. on May 22, 2024, at an exercise price of $0.451.

Director Vickie S. Reed of Evoke Pharma, Inc. reports the acquisition of stock options.

Director Kenneth J. Widder acquired stock options in Evoke Pharma, Inc. on May 22, 2024.

Director Todd C. Brady acquired stock options in Evoke Pharma, Inc. on May 22, 2024.